Type 2 Diabetes Mellitus (T2DM) is a complex endocrine and metabolic disorder with an increasing prevalence and considerable health and economic consequences. For many years, evidences from pharmacogenomics, being at the forefront of precision medicine, indicated that genetic variations can affect the pathogenesis of T2DM and response to treatment with antidiabetic drugs. Recently, pharmacomicrobiomics, an extension of pharmacogenomics, is investigating the potential mechanism of the microbiome to drug response. The imbalance of human gut microbiota and their metabolites are increasingly considered to play a critical role in the development of T2DM, pharmacokinetics, pharmacodynamics, and treatment outcomes of antidiabetic drugs. Future research is needed to focus on the impact of both genetic and microbiome variations in the pathogenesis of T2DM development and therapeutic responses toward antidiabetic drugs. The combination of pharmacogenomics and pharmacomicrobiomics will help us gain improved personalized management of T2DM.
In this Research Topic, we will focus on new findings in the emerging fields of pharmacogenomics and pharmacomicrobiomics for T2DM treatment, ranging from basic experimental studies to clinical translational research. This Research Topic aims to provide a better understanding of genetic and/or microbiome variations to the underlying regulatory mechanism of T2DM development, pharmacokinetics, pharmacodynamics and therapeutic responses toward antidiabetic drugs.
We welcome the submission of Original Research, Systemic Review, Meta-analysis, Methods, Review, and Hypothesis and Theory on this scope but not limited to topics below:
(1) Identification of novel genetic and epigenetic regulatory mechanisms in the susceptibility of T2DM and related traits.
(2) The potential influence of genetic variations in the pharmacokinetic mechanisms of antidiabetic drugs.
(3) Identification of novel genetic and epigenetic markers of T2DM prognosis, drug response and/or adverse events.
(4) The role of gut microbiota in the pathophysiology of T2DM and related traits.
(5) The potential influence of intestinal microbiota in the pharmacokinetic mechanisms of antidiabetic drugs.
(6) The role of drug-microbiome interactions in the response to antidiabetic therapies.
(7) Current status and future developments in pharmacogenomics and pharmacomicrobiomics of T2DM treatment.
Type 2 Diabetes Mellitus (T2DM) is a complex endocrine and metabolic disorder with an increasing prevalence and considerable health and economic consequences. For many years, evidences from pharmacogenomics, being at the forefront of precision medicine, indicated that genetic variations can affect the pathogenesis of T2DM and response to treatment with antidiabetic drugs. Recently, pharmacomicrobiomics, an extension of pharmacogenomics, is investigating the potential mechanism of the microbiome to drug response. The imbalance of human gut microbiota and their metabolites are increasingly considered to play a critical role in the development of T2DM, pharmacokinetics, pharmacodynamics, and treatment outcomes of antidiabetic drugs. Future research is needed to focus on the impact of both genetic and microbiome variations in the pathogenesis of T2DM development and therapeutic responses toward antidiabetic drugs. The combination of pharmacogenomics and pharmacomicrobiomics will help us gain improved personalized management of T2DM.
In this Research Topic, we will focus on new findings in the emerging fields of pharmacogenomics and pharmacomicrobiomics for T2DM treatment, ranging from basic experimental studies to clinical translational research. This Research Topic aims to provide a better understanding of genetic and/or microbiome variations to the underlying regulatory mechanism of T2DM development, pharmacokinetics, pharmacodynamics and therapeutic responses toward antidiabetic drugs.
We welcome the submission of Original Research, Systemic Review, Meta-analysis, Methods, Review, and Hypothesis and Theory on this scope but not limited to topics below:
(1) Identification of novel genetic and epigenetic regulatory mechanisms in the susceptibility of T2DM and related traits.
(2) The potential influence of genetic variations in the pharmacokinetic mechanisms of antidiabetic drugs.
(3) Identification of novel genetic and epigenetic markers of T2DM prognosis, drug response and/or adverse events.
(4) The role of gut microbiota in the pathophysiology of T2DM and related traits.
(5) The potential influence of intestinal microbiota in the pharmacokinetic mechanisms of antidiabetic drugs.
(6) The role of drug-microbiome interactions in the response to antidiabetic therapies.
(7) Current status and future developments in pharmacogenomics and pharmacomicrobiomics of T2DM treatment.
